Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2004-12-30
2009-08-25
Tran, S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S451000, C424S464000, C424S489000, C514S557000, C514S561000
Reexamination Certificate
active
07579020
ABSTRACT:
An oral formulation of arginine α-ketoglutarate is disclosed which formulation is comprised of arginine α-ketoglutarate and one or more excipient materials. A wide range of different controlled release formulations will be apparent to those skilled in the art upon reading this disclosure. The formulation of arginine α-ketoglutarate and excipient material is designed to obtain a desired result, e.g. attenuate symptoms suffered by a patient with a glutamate dehydrogenase deficiency or increase prolyl hydroxylase and lysyl hydroxylase activity or prevent protein glycation characteristic of atheroscloerosis, cataract formation, retinopathy, and aging. The desired results are obtained by increasing the period of time that a therapeutic level of arginine α-ketoglutarate is continuously maintained in the patient. The therapeutic level as well as the period of time over which that level must be maintained can vary between patient based on a range of factors such as the condition of the patient and the patient's reactivity to arginine α-ketoglutarate. However, the period of time will be greater than that obtained with a conventional quick release arginine α-ketoglutarate formulation.
REFERENCES:
patent: 3577551 (1971-05-01), Murakami et al.
patent: 4461759 (1984-07-01), Dunn
patent: 4520009 (1985-05-01), Dunn
patent: 4705867 (1987-11-01), Giray et al.
patent: 4800044 (1989-01-01), Giray et al.
patent: 4966732 (1990-10-01), Giray et al.
patent: 5217997 (1993-06-01), Levere et al.
patent: 5334612 (1994-08-01), Kalden et al.
patent: 5376382 (1994-12-01), Goede et al.
patent: 5455264 (1995-10-01), Beisswenger et al.
patent: 5505962 (1996-04-01), Sparks
patent: 5527539 (1996-06-01), Sarlikiotis et al.
patent: 5532269 (1996-07-01), Koltringer
patent: 5569670 (1996-10-01), Weischer et al.
patent: 5599835 (1997-02-01), Fischer
patent: 5616345 (1997-04-01), Geoghegan et al.
patent: 5637320 (1997-06-01), Bourke et al.
patent: 5641515 (1997-06-01), Ramtoola
patent: 5641745 (1997-06-01), Ramtoola
patent: 5646187 (1997-07-01), Vinnars et al.
patent: 5650429 (1997-07-01), Conrad et al.
patent: 5691379 (1997-11-01), Ulrich et al.
patent: 5693664 (1997-12-01), Wessel et al.
patent: 5705192 (1998-01-01), Bethge et al.
patent: 5728735 (1998-03-01), Ulrich et al.
patent: 5730988 (1998-03-01), Womack
patent: 5827643 (1998-10-01), Conrad et al.
patent: 6197340 (2001-03-01), Byrd et al.
patent: 6544563 (2003-04-01), Wuh et al.
patent: 6544994 (2003-04-01), Rabelink et al.
patent: 6548087 (2003-04-01), Kent et al.
patent: 6552074 (2003-04-01), Kimoto et al.
patent: 6572888 (2003-06-01), Byrd
patent: 6608109 (2003-08-01), Allen
patent: 6686340 (2004-02-01), Rath
patent: 6696072 (2004-02-01), Podolski
patent: 6713079 (2004-03-01), Usala
patent: 6727285 (2004-04-01), Haik, Jr.
patent: 6805883 (2004-10-01), Chevaux et al.
patent: 6905707 (2005-06-01), Byrd
patent: 2002/0004515 (2002-01-01), Smith
patent: 2002/0068365 (2002-06-01), Kuhrts
patent: 2003/0108624 (2003-06-01), Kosbab
patent: 2003/0228360 (2003-12-01), Han et al.
patent: 2004/0006140 (2004-01-01), Kaesemeyer
patent: 2004/0023889 (2004-02-01), Gardiner
patent: 2004/0242682 (2004-12-01), Kaesemeyer
patent: 2005/0049428 (2005-03-01), Vennerstrom
patent: 1 668 887 (1971-07-01), None
patent: 36 29 116 (1988-03-01), None
patent: 42 20 851 (1993-01-01), None
patent: 43 17 646 (1994-12-01), None
patent: 43 38 508 (1995-05-01), None
patent: 43 43 592 (1995-06-01), None
patent: 43 43 647 (1995-06-01), None
patent: 44 00 269 (1995-07-01), None
patent: 44 47 599 (1996-07-01), None
patent: 0 733 363 (1996-03-01), None
patent: 60-184011(A) (1985-09-01), None
patent: WO 89/03688 (1989-05-01), None
patent: WO 98/57627 (1998-12-01), None
Armstrong et al.,Free Radical Biology and Chemistry, (1996) 21(5):719-726.
Barbiroli et al.,J Neurol, (1995) 242:472-477.
Baur et al.,Klin Wochenschr, (1991) 69:722-724.
Bilich et al.,I-Pharmacodynamics, (1978) 88:93.
Black et al.,Clinical and Experimental Pharmacology and Physiology, (1998) 25:712-714.
Bloomgarden,Diabetes Care, (Apr. 1997) 20(4):670-673.
Burkart et al.,Agents Actions, (1993) 38:60-65.
Busse et al.,Arzneim-Forsch/Drug Research(1992) 42(6):829-831.
Bustamante et al.,Free Radical Biology and Medicine, (1998) 24(6):1023-1039.
Carreau,Methods in Enzymology, (1979) 62:152-158.
Cesolari et al.,Rev Exp Enf Ap Digest, (1988) 73(3) 229-232.
Chen et al.,Archives of Biochemistry and Biophysics, (1997) 338(2):165-172.
Chokroverty et al.,Neurology, 35(5):652-9 (1985).
Cynober,Curr Opin Clin Nutr Metab Care, 2(1):33-7 (1999).
Devasgayam et al.,Chem-Biol Interactions, (1993) 86:79-92.
Dimpfel et al.,Dev Pharmacol Ther, (1990) 14:193-199.
Egan et al.,Prostaglandins, (1978) 16(6):861-869.
Estrada et al.,Diabetes, (Dec. 1996) 45:1798-1804.
Faust et al.,J. Immunopharmac, (1994) 16(1):61-66.
Fuchs et al.,Skin Pharmacol, (1994) 7:278-284.
Gandhi et al.,J Biosci, (Sep. 1985) 9 (1 & 2):117-127.
Garrett et al.,Neuroscience Letters, (1997) 222:191-194.
Gerbitz et al.,Diabetes, (Feb. 1996) 45:113-126.
Hammarqvist et al.,Crit Care Med, (1997) 25(1):78-84.
Haugaard et al.,Biochem Biophys Acta, (1970) 222:583-586.
Henricksen et al.,American Physiological Society, (1990) C648-C653.
Henricksen et al.,Life Sciences, (1997) 61(8):805-812.
Hofmann et al.,Archives of Biochemistry and Biophysics, (1995) 324(1):85-92.
Jacob et al.,Diabetes, (1995) 245-250.
Jacob et al.,Diabetes, (Aug. 1996) 45:1024-1029.
Kagan et al.,Biochemical Pharmacology, (1992) 44(8):1637-1649.
Kagan et al.,Journal of Lipid Research, (1992) 33:385-397.
Kagan et al.,Free Rad Res Comms, (1991) 15(5):265-276.
Khamaisi et al.,Metabolism, (Jul. 1997) 45(7):763-768.
Kuttan,J. Nutr., 110(8):1525-32 (1980).
Lavis et al.,The Journal of Biologic Chemistry, (Jan. 10, 1970) 245(1):23-31.
Lodge et al.,Journal of Applied Nutrition, (1997) 49 (1 & 2)3-11.
Lodge et al.,Free Radical Biology&Medicine, (1998) 25(3):287-297.
Matsugo et al.,Biochemistry and Molecular Biology International, (Oct. 1995) 37(2)375-383.
Merin et al.,FEBS Letters, (1996) 294:9-13.
Muller et al.,Toxicology, (1989) 58:175-185.
Muller et al.,Biochimica et Biophysica Acta, (1990) 1052:386-389.
Muller et al.,Journal of Cerebral Blood Flow and Metabolism, (1995) 15:624-630.
Muting et al., MMW Munch Med Wochenschr, 119(16):538-8 (1977).
Nagamatsu et al.,Diabetes Care, (1995) 18(8):1160-1167.
National Diabetes Data Group Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance,Diabetes(1979) 28:1039-1057.
Natraj et al.,J. Biosci, (1984) 6(1):38-46.
Nickander et al.,Free Radical Biology&Medicine(1996) 21(5):631-639.
Ohmori et al.,Japan J. Pharmacol, (1986) 42:275-2.
Ohmori et al.,Japan J. Pharmacol, (1986) 42:135-140.
Ou et al.,Free Rad Res, (1996) 25(4):337-346.
Ou et al.,Biochemical Pharmacology, (1995) 50(1):123-126.
Packer et al.,Free Radical Biology&Medicine, (1997) 22(1/2):359-378.
Packer et al.,Free Radical Biology&Medicine, (1995) 19(2):227-250.
Packer,Diabetologica, (1993) 36:1212-1213.
Pascoe et al.,Free Radical Biology&Medicine, (1989) 6:209-224.
Peinado et al.,Archives of Biochemistry and Biophysics, (Sep. 1989) 273(2):389-395.
Plaitakis et al.,Ann Neurol, 7(4):297-303 (1980).
Podda et al.,Biochemical Pharmacology, (1996) 52:627-633.
Prehn et al.,Journal of Cerebral Blood Flow and Metabolism(1992) 12:78-87.
Reed et al.,Science, (1951) 93-94.
Roy et al.,Biochemical Pharmacology, (1997) 53:393-399.
Scheer et al.,Archives of Biochemistry and Biophysics, (May 1, 1993) 302(2):385-390.
Schmid et al.,FASEB Journal, (Jul. 1998) 12:863-870.
Schonheit et al.,Biochimica et Biophysica Acta, (1995) 1271:335-342.
Segermann et al.,Arzneim.-Forsch./Drug Res., (1991) 41(12):1294-1298.
Sen et al.,The FASEB Journal, (May 1996) 10:709-720.
Sen et al.,Free Radical Biology&Medicine, (1997) 22(7):1241-1257.
Sen et al.,Biochemical and Biophysical Research Communications(1998) 247:223-228.
Simopoulos,Nutrition Today, (Jan./Feb. 1994) 12-16.
Stoll et al.,Pharmacology Biochemistry and Behavior, (1993) 46:799-805.
Streeper et al.,America
Bozicevic Karl
Bozicevic Field & Francis LLP
Medical Research Institute
Tran S.
LandOfFree
Controlled release arginine α-ketoglutarate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlled release arginine α-ketoglutarate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled release arginine α-ketoglutarate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4138303